Nasus Pharma (NSRX) announced the appointment of Eyal Rubin as Executive Vice President, EVP, and Chief Financial Officer, CFO. Rubin brings more than two decades of financial leadership experience in global biotechnology and pharmaceutical industries to Nasus Pharma’s executive leadership team. Rubin will lead and oversee Nasus Pharma’s financial operations, including corporate finance, financial planning, capital strategy, and investor relations.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSRX:
- Nasus Pharma announces initiation of Phase 2 study of NS002
- Nasus Pharma Initiates Phase 2 Study of Needle-Free Epinephrine
- Nasus Pharma approved by Health Canada to start Phase 2 study of NS002
- Nasus Pharma Updates Corporate Presentation
- Nasus Pharma participates in conference call hosted by Citizens JMP